Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…
Abstract Number: 0690 • ACR Convergence 2022
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Ajay Tambralli¹, Alyssa Harbaugh¹, Christine Rysenga¹, Kaitlyn Sabb¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Yu (Ray) Zuo¹ and Jason S Knight², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…
Abstract Number: 0691 • ACR Convergence 2022
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
Hannah Britt¹, Hannah Bradford¹, Valentina Spiteri¹, Anisur Rahman², Ian Giles¹, Mihaela Delcea³, Paul Dalby¹, Kostas Thalassinos¹ and Thomas McDonnell¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³University of Greifswald, Greifswald, Germany
Background/Purpose: Beta-2-Glycoprotein I (B2GPI) is a serum protein of approximately 50kDa and is the main autoantigen of Antiphospholipid syndrome (APS). Antibodies to B2GPI (aB2GPI) are…
Abstract Number: 0676 • ACR Convergence 2022
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Jeffrey X. Yang¹, Hannah Langenfeld², Prerna Dogra¹, Irina Bancos³, Hassan Murad³, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
Abstract Number: 0692 • ACR Convergence 2022
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
Naveen Kumar S K¹, Claire Hoy¹, Christine Rysenga¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Sherwin Navaz¹, Jacqueline Madison¹, Jason S Knight³ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…
Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0693 • ACR Convergence 2022
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Naveen Kumar S K¹, Claire Hoy¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Kaitlyn Sabb¹, Christine Rysenga¹, Jacqueline Madison¹, Yu Zuo¹ and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: By converting extracellular ATP into homeostatic adenosine, the ectonucleotidases CD39 (ATP to AMP) and CD73 (AMP to adenosine) dictate extracellular purinergic gradients and as…
Abstract Number: 0678 • ACR Convergence 2022
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
Patompong Ungprasert¹, Sunisa Kongkiatkamon², Ben Ponvilawan³, Nuttavut Sumransub⁴ and Paul Kroner⁵, ¹Cleveland Clinic, Cleveland Heights, OH, ²Chulalongkorn University, Bangkok, Thailand, ³Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁴University of Minnesota, Minneapolis, MN, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, morbidity, mortality and resource utilization of patients with antiphospholipid syndrome (APS). The purpose of this study is to…
Abstract Number: 0694 • ACR Convergence 2022
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Maria Laura Bertolaccini¹, Yiannis Ioannou², Helen Neale³, Prakash Saha¹ and Alberto Smith¹, ¹King's College London, London, United Kingdom, ²UCB Biopharma SRL, London, United Kingdom, ³UCB Biopharma SRL, Slough, United Kingdom
Background/Purpose: FcRn (the neonatal Fc receptor) is a receptor expressed by antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, as well as on neutrophils.…
Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Faria Sami, Dennis Kumi and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…
Abstract Number: 0943 • ACR Convergence 2022
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
Hiba Bilal¹, Amarah Baluch² and Andras Perl³, ¹SUNY Upstate Medical Unviersity, Jamesville, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Women of child-bearing age with underlying rheumatic disease such as systemic lupus erythematous (SLE) with positive anti-phospholipid antibodies (aPL) are at an increased risk…
Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Medha Barbhaiya¹, Deanna Jannat-Khah, DrPH, MSPH¹, Jonah Levine¹, Karen Costenbader² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…
Abstract Number: 1066 • ACR Convergence 2022
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
Elvis Hysa, Carmen Pizzorni, Silvia Sammori, Emanuele Gotelli, Andrea Pogna, andrea cere, Carlotta Schenone, Veronica Gerli, sabrina Paolino, Alberto Sulli and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: Nailfold videocapillaroscopy (NVC) allows the safe and fast detection of different microvascular patterns in patients affected by autoimmune connective tissue diseases (CTDs). The prevalence of…
Abstract Number: 0681 • ACR Convergence 2022
Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study
Yu (Ray) Zuo¹, Sherwin Navaz¹, Wenying Liang¹, Chun Li², Colby Ayers³, Christine Rysenga¹, Alyssa Harbaugh¹, Gary Norman⁴, Elizabeth Solow³, Dami Akinmolayemi⁵, Anand Rohatgi³, David Karp⁶, Jason S Knight⁷ and James de Lemos³, ¹University of Michigan, Ann Arbor, MI, ²People's Hospital Peking University, Beijing, China, ³UT Southwestern Medical Center, Dallas, TX, ⁴Werfen, San Diego, ⁵Columbia University, New York, NY, ⁶UT Southwestern, Dallas, TX, ⁷University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: While circulating antiphospholipid antibodies (aPL) are recognized as an important acquired risk factor for thrombotic events, the prevalence of aPL in the general population…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].